Literature DB >> 7543033

Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum.

K Mitrunen1, K Pettersson, T Piironen, T Björk, H Lilja, T Lövgren.   

Abstract

We developed a simple one-step dual-label immunoassay for simultaneous measurement of the free, noncomplexed form of prostate-specific antigen (PSA) and total PSA. The assay is based on time-resolved fluorescence and includes a stable fluorescent chelate of Eu to label a monoclonal antibody (mAb) that detects only free PSA, whereas a second mAb labeled with a fluorescent chelate of Tb provides equimolar detection of both free PSA and PSA complexed to alpha 1-antichymotrypsin. A third mAb on a solid phase captures the free and complexed forms of PSA in an equimolar fashion. The simultaneous measurement of the free-to-total PSA ratio (F/T) with the one-step dual assay is not sensitive to variations in the sample volume. The discrimination between benign prostatic hyperplasia and prostate cancer patients, i.e., the area under the receiver-operating characteristic curve, increased from 0.64 (total PSA assay) to 0.78 and 0.81 when the F/T ratio was measured with single and dual assays, respectively.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543033

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  42 in total

1.  Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.

Authors:  Thomas Steuber; Andrew J Vickers; Alexander Haese; Charlotte Becker; Kim Pettersson; Felix K-H Chun; Michael W Kattan; James A Eastham; Peter T Scardino; Hartwig Huland; Hans Lilja
Journal:  Int J Cancer       Date:  2006-03-01       Impact factor: 7.396

2.  Identification of a novel proteoform of prostate specific antigen (SNP-L132I) in clinical samples by multiple reaction monitoring.

Authors:  Akos Végvári; Karin Sjödin; Melinda Rezeli; Johan Malm; Hans Lilja; Thomas Laurell; György Marko-Varga
Journal:  Mol Cell Proteomics       Date:  2013-07-10       Impact factor: 5.911

3.  Simultaneous determination of free and total prostate-specific antigen by a magnetic particle-based time-resolved fluoroimmunoassay.

Authors:  Bin Zhou; Jue Zhang; Zhongwei Lv; Jun Fan; Yi Zhang; Biao Huang
Journal:  J Clin Lab Anal       Date:  2017-01-19       Impact factor: 2.352

4.  A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.

Authors:  Katharina Braun; Daniel D Sjoberg; Andrew J Vickers; Hans Lilja; Anders S Bjartell
Journal:  Eur Urol       Date:  2015-05-13       Impact factor: 20.096

5.  A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.

Authors:  Melissa Assel; Liisa Sjöblom; Teemu J Murtola; Kirsi Talala; Paula Kujala; Ulf-Håkan Stenman; Kimmo Taari; Anssi Auvinen; Andrew Vickers; Tapio Visakorpi; Teuvo L Tammela; Hans Lilja
Journal:  Eur Urol Focus       Date:  2017-11-11

6.  Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.

Authors:  Daniel D Sjoberg; Andrew J Vickers; Melissa Assel; Anders Dahlin; Bing Ying Poon; David Ulmert; Hans Lilja
Journal:  Eur Urol       Date:  2018-03-05       Impact factor: 20.096

7.  Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.

Authors:  Pär Stattin; Andrew J Vickers; Daniel D Sjoberg; Robert Johansson; Torvald Granfors; Mattias Johansson; Kim Pettersson; Peter T Scardino; Göran Hallmans; Hans Lilja
Journal:  Eur Urol       Date:  2015-02-11       Impact factor: 20.096

8.  Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

Authors:  Andrew J Vickers; Angel M Cronin; Thomas Björk; Jonas Manjer; Peter M Nilsson; Anders Dahlin; Anders Bjartell; Peter T Scardino; David Ulmert; Hans Lilja
Journal:  BMJ       Date:  2010-09-14

9.  NF-kappaB regulates androgen receptor expression and prostate cancer growth.

Authors:  Liying Zhang; Saleh Altuwaijri; Fangming Deng; Lishi Chen; Priti Lal; Umeshkumar K Bhanot; Ruslan Korets; Sven Wenske; Hans G Lilja; Chawnshang Chang; Howard I Scher; William L Gerald
Journal:  Am J Pathol       Date:  2009-07-23       Impact factor: 4.307

10.  External quality assessment of tumour marker analysis: state of the art and consequences for estimating diagnostic sensitivity and specificity.

Authors:  Hans Reinauer; William Graham Wood
Journal:  Ger Med Sci       Date:  2005-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.